Dynavax weakness a buying opportunity, says JMP Securities
JMP Securities believes Dynavax will be able to address many of the FDA panel's concerns and sees a good chance the company's vaccine is approved. The firm recommends buying Dyax shares on weakness and keeps an Outperform rating on the name with a $6 price target.
Terms and Privacy Policy